Why TRVI rose 16% since Nov 5
Up 16% from Nov 5 to Nov 10.
- Trevi Therapeutics rose 16% from Nov 5 to Nov 10. 12 points of it came on Nov 6.
1 more reason, free with an account →The timeline and its peers, for Pro members.
Trevi Therapeutics (TRVI) stock
$14.91
Quality Score
-1
In its industry
#148of 281
Checks firing
2of 14
From 52-week high
-26.3%
TRVI's Quality Score fell 2 points on Tue, Nov 10, to -1. Buying slipped from its highest in 20 days (2 chart checks stopped).
Follow TRVI's trial news. Pro members can get an alert when Trevi Therapeutics files news, and see its trials, share raises, and its CEO's filings.
Get an alert when TRVI files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
NextQ1 2027“…program held in October 2026; Phase 2 dose-ranging trial expected to initiate in the first quarter of 2027”
Key facts on TRVI
| Holding it back | A $61M loss |
| Latest filing | 8-K, Nov 9 |
1 more reason behind TRVI's -1, free with an account →3 more reasons behind TRVI's -1, for Pro members.
TRVI in the news
ReportLast night: a loss of $0.13 a share. Past reports ›
Mon Nov 9Trevi Therapeutics faces earnings test as chronic cough trials advance By Investing.com
What's next
Wed Nov 11: Stifel Healthcare Conference 2026Investor conference · date confirmed.
TRVI catalysts
Coming up
After its last 4 reports it closed -2.4% on average, higher 1 of 4 times.
What's next for TRVI, and how long its cash lasts
Next step the company has named
Q1 2027“Positive meeting with the FDA on the non-IPF ILD-related chronic cough program held in October 2026; Phase 2 dose-ranging trial expected to initiate in the first quarter of 2027”
Cash runway
The company says its cash lasts into 2030 (8-K, Nov 9).
Dilution on the horizon
- Shelf registration (S-3ASR, filed Nov 13, 2025)
- At-the-market share sales program (S-3ASR, filed Nov 13, 2025)
Insiders
Director Michael Thomas Heffernan sold 39,473 shares on Sep 15, under a planned sale.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Why TRVI scores -1
Poorfor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means
- +2Chart checks 2 of 14 firing right now, one point each
- +1Long-term trend above a flat or falling 200-day average
- Profit subtracts
- Dilution subtracts
- Volatility subtracts
- Cash flow subtracts
What every line is worth, and the reason behind it, on TRVI and every other stock.Get in free →
How TRVI ranks in Biotech
TRVI is #148 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 148 |
When does TRVI report earnings, and what happens after?
Expected to report Tue Mar 16, after the close (in 126 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
What TRVI reported on Nov 9, 2026
The quarter
A loss of $0.13 a share, from $0.08.
“R&D expenses for the third quarter of 2026 increased to $19.1 million from $10.1 million in the same period in 2025, primarily due to increased clinical development expenses associated with the Phase 3 OCEAN-1 trial, the Phase 2b LAKE trial, and the Phase 3 OCEAN-2 trial as well as increases in stock-based compensation and personnel-related expenses.”
Where the sales came from
TRVI's results filing gives no sales by line in a table we read.
The outlook
No outlook figures read from this release.
In the company's words
“The Company expects its current cash, cash equivalents and marketable securities will provide cash runway into 2030 and fund the development of Haduvio for the treatment of patients with IPF-related chronic cough, through potential FDA approval.”
From its results filing (SEC filing · Nov 9)
The numbers
- $1.8B
- today
- -$61.7M
- last 12 months
Close after the report, last 3
-2.7%+0.1%-2.6%
May 5Aug 6Nov 9
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 9, 2026 | -7.8% | -2.6% | not yet |
| Aug 6, 2026 | +4.1% | +0.1% | -1.9% |
| May 5, 2026 | -3.5% | -2.7% | +0.7% |
TRVI has 2 of 14 chart checks firing
The other 10 checks on TRVI, and all 14 on every stock.Get in free →
TRVI RSI today: 59.6, above its 50-day and 200-day averages
RSI 59.6, MACD above signal, above both averages. Not scored.
The deep dive on TRVI
- What it does and how it makes money
- Where it standsSEC filing · Apr 17, 2026
- Who holds and trades it
TRVI's officers and directors
Officers and directors with a Form 4 in the last 12 months.
Which ETFs hold TRVI?
In ETFs: TRVI is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
About Trevi Therapeutics
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
Pro members see every line of every stock's score.
- What would turn TRVI's score around: 8 things
- 5 more filings explained, a plain line each
- Real-time prices, no delay
Straight AnswersStraight Answers
What does TRVI's Quality Score say?
TRVI scores -1 today, which Breakaway calls Poor. It is #148 of 281 in Biotech by Quality Score, with 2 of 14 chart checks firing. Up 16% from Nov 5 to Nov 10. Shares: 10.1% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
What is TRVI's Quality Score?
TRVI scores -1 today, which Breakaway calls Poor (below zero). That is #148 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind TRVI's -1.
When does TRVI report earnings?
Expected to report Tue Mar 16, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. TRVI closed higher after 1 of its last 4 reports. Past behavior, not a forecast.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.